Drug intelligence / Profile preview

maraviroc + favipiravir

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of maraviroc, a CCR5 antagonist, and favipiravir, an antiviral RNA-dependent RNA polymerase inhibitor. This combination has been studied for the treatment of COVID-19, with the rationale that maraviroc could modulate inflammation while favipiravir inhibits viral replication. Studies have shown that the combination plus systemic steroids may have a larger effect on decreasing viral load compared to systemic steroids alone or with just one of these drugs.

Targets

CCR5 (C-C chemokine receptor type 5)RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on maraviroc + favipiravir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on maraviroc + favipiravir.

Explore the full profile